Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest [Yahoo! Finance]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Yahoo! Finance
ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted closer scrutiny of how the stock's latest price action lines up with its fundamentals. See our latest analysis for ArriVent BioPharma. At a share price of $24.89, ArriVent BioPharma has a 7 day share price return of 16.15% and a 90 day share price return of 19.66%, while the 1 year total shareholder return stands at 51.58%. This suggests that momentum has been building, despite a softer 30 day share price return of 1.43%. If you are considering other oncology and biotech related ideas, this is a useful moment to widen your watchlist with a curated set of healthcare AI names via the 36 healthcare AI stocks With ArriVent BioPharma posting strong recent returns and trading at a discount to the current analyst price target and intrinsic estimates, the key question is whether this represents an undervalued growth opportunity or
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? [Yahoo! Finance]Yahoo! Finance
- ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]Seeking Alpha
- ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
AVBP
Earnings
- 3/5/26 - Miss
AVBP
Sec Filings
- 3/17/26 - Form 8-K
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- AVBP's page on the SEC website